Aldehyde oxidase and its contribution to the metabolism of a structurally novel, functionally selective GABAA α5-subtype inverse agonist

Xenobiotica

Volumn 36, Issue 4, 2006, Pages 315-330

  O'Connor, D ^a   Jones, P ^a   Chambers, M S ^a   Maxey, R ^a   Szekeres, H J ^a   Szeto, N ^a   Scott Stevens, P ^a   Macleod, A M ^a   Braun, M ^b   Cato, B ^b  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Aldehyde oxidase; Metabolic routes; Xanthine oxidase

Indexed keywords

3 TERT BUTYL 7 (5 METHYLISOXAZOL 3 YL) 2 (1 METHYL 1H 1,2,4 TRIAZOL 5 YLMETHOXY)PYRAZOLO[1,5 D][1,2,4]TRIAZINE; 4 AMINOBUTYRIC ACID A ALPHA5 RECEPTOR INVERSE AGONIST; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ALDEHYDE OXIDASE; CYTOCHROME P450; DRUG METABOLITE; ENZYME INHIBITOR; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COGNITION; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OXIDATION; RAT; RHESUS MONKEY;

ALDEHYDE OXIDASE; ANIMALS; CHROMATOGRAPHY, LIQUID; CYTOSOL; DOGS; DRUG DESIGN; HUMANS; LIVER; MACACA MULATTA; MASS SPECTROMETRY; RATS; RECEPTORS, GABA-A; SUBCELLULAR FRACTIONS; XANTHINE OXIDASE;

ANIMALIA; CANIS FAMILIARIS; MACACA MULATTA;

EID: 33646808612     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600567903     Document Type: Article

References (21)

1. Acheampong AA, Chien DS, Lam S, Vekich S, Breau A, Usansky J, Harcourt D, Munk SA, Nguyen H, Garst M, Tang-Liu D. 1996. Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 26:1035-1055.
2. Austin NE, Baldwin SJ, Cutler L, Deeks N, Kelly PJ, Nash M, Shardlow CE, Stemp G, Thewlis K, Ayrton A, Jeffrey P. 2001. Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: In vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 31:677-686.
3. Beedham C. 1987. Molybdenum hydroxylases: Biological distribution and substrate-inhibitor specificity. Progress in Medicinal Chemistry 24:85-127.
4. Beedham C. 1998. Oxidation of carbon via molybdenum hydroxylases. In: Gooderham N, Jenner P, Patterson L, editors. Drug metabolism: towards the next millennium. Amsterdam: IOS Press. pp. 39-52.
5. A α5 receptors with cognition enhancing properties. Journal of Medicinal Chemistry 47:5829-5832.
6. Cole SO. 1986. Effects of benzodiazepines on acquisition and performance: A critical assessment. Neuroscience and Biobehavioral Reviews 10:265-272.
7. Dorow R, Horowski R, Paschelke G, Amin M, Braestrup C. 1983. Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors. Lancet 322:98-99.
8. Filer CW, Ramji JV, Allen GD, Brown TA, Fowles SE, Hollis FJ, Mort EE. 1995. Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. Xenobiotica 25:477-490.
9. Ghoneim MM, Mewaldt SP. 1990. Benzodiazepines and human memory: A review. Anesthesiology 72:926-938.
10. A α5 inverse agonist for cognitive dysfunction. Bioorganic and Medicinal Chemistry Letters 16: 872-875.
11. Kaye B, Offerman JL, Reid JL, Elliott HL, Hillis WS. 1984. A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica 14:935-945.
12. Kaye B, Rance DJ, Waring L. 1985. Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man. Xenobiotica 15:237-242.
13. Kitamura S, Nakatani K, Sugihara K, Ohta S. 1999a. Strain differences of the ability to hydroxylate methotrexate in rats. Comparative Biochemistry and Physiology Part C 122:331-336.
14. Kitamura S, Sugihara K, Nakatani K, Ohta S, Oh-Hara T, Ninomiya S, Green CE, Tyson CA. 1999b. Variation in hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 48:607-611.
15. Krenitsky TA. 1973. Xanthine oxidase and aldehyde oxidase in purine and purine analogue metabolism. Advances in Experimental Medicine and Biology 41:57-64.
16. Krenitsky TA, Hall WW, de Miranda P, Beauchamp LM, Schaeffer HJ, Whiteman PD. 1984. 6-Deoxyacyclovir: A xanthine oxidase-activated prodrug of acyclovir. Proceedings of the National Academy Sciences, USA 81:3209-3213.
17. Little HJ, Nutt DJ, Taylor SC. 1984. Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: Proconvulsant properties and kindling. British Journal of Pharmacology 83:951-958.
18. Lu P, Kari P, Rodrigues D, O'Connor D, Chambers M, Jones P, Shou M. 2005. Characterization of human liver microsomal cytochromes P450 involved in the metabolism of compound I. Drug Metabolism Reviews 37 (Suppl. 2): 199. [Abstract from the 13th NA ISSX/20th JSSX Meeting, Maui, HI, USA].
19. Petersen EN. 1983. DMCM: A potent convulsive benzodiazepine receptor ligand. European Journal of Pharmacology 94:117-124.
20. Rashidi MR, Smith JA, Clarke SE, Beedham C. 1997. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metabolism and Disposition 25:805-813.
21. Watt AP, Morrison D, Locker KL, Evans DC. 2000. Higher throughput bioanalysis by automation of a protein precipitation assay using a 96-well format with detection by LC-MS/MS. Analytical Chemistry 72:979-984.